^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Vesanoid (tretinoin)

    i
    Other names: ATRA, Ro 5488, NSC 122758, NSC-122758, Ro-5488, NSC122758, Ro5488
    Company:
    Roche
    Drug class:
    Cytotoxic T lymphocyte stimulant, Telomerase inhibitor, Retinoic acid receptor agonist
    Related drugs:
    24d
    All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Dwight Owen | Suspended --> Active, not recruiting | Trial completion date: Oct 2025 --> Jan 2026 | Trial primary completion date: Oct 2025 --> Jan 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    Tecentriq (atezolizumab) • Vesanoid (tretinoin)
    2ms
    KEYMAKER-U02 Substudy 02C: Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02) (clinicaltrials.gov)
    P1/2, N=146, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed | N=90 --> 146
    Trial completion • Enrollment change
    |
    Vesanoid (tretinoin) • vibostolimab (MK-7684) • Cavatak (gebasaxturev) • MK-4830 • favezelimab/pembrolizumab (MK-4280A)
    2ms
    All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=18, Suspended, Dwight Owen | Recruiting --> Suspended
    Trial suspension
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    Tecentriq (atezolizumab) • Vesanoid (tretinoin)
    3ms
    KEYMAKER-U02 Substudy 02A: Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02) (clinicaltrials.gov)
    P1/2, N=100, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed | N=200 --> 100 | Trial completion date: Apr 2030 --> Aug 2025 | Trial primary completion date: Apr 2030 --> Aug 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Vesanoid (tretinoin) • quavonlimab (MK-1308) • vibostolimab (MK-7684)
    3ms
    KEYMAKER-U02 Substudy 02C: Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02) (clinicaltrials.gov)
    P1/2, N=90, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Apr 2030 --> Oct 2025 | Trial primary completion date: Apr 2030 --> Oct 2025
    Trial completion date • Trial primary completion date
    |
    Vesanoid (tretinoin) • vibostolimab (MK-7684) • Cavatak (gebasaxturev) • MK-4830 • favezelimab/pembrolizumab (MK-4280A)
    3ms
    All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=18, Recruiting, Dwight Owen | Trial completion date: Jul 2025 --> Oct 2025 | Trial primary completion date: Jul 2025 --> Oct 2025
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    Tecentriq (atezolizumab) • Vesanoid (tretinoin)
    6ms
    Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=80, Enrolling by invitation, Institute of Hematology & Blood Diseases Hospital, China | Recruiting --> Enrolling by invitation | Trial completion date: Dec 2022 --> Oct 2027 | Trial primary completion date: Dec 2021 --> May 2026
    Enrollment status • Trial completion date • Trial primary completion date
    |
    NPM1 (Nucleophosmin 1)
    |
    NPM1 mutation
    |
    cytarabine • Vesanoid (tretinoin) • arsenic trioxide
    9ms
    All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=18, Recruiting, Dwight Owen | Trial completion date: Dec 2024 --> Jul 2025 | Trial primary completion date: Dec 2024 --> Jul 2025
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    Tecentriq (atezolizumab) • Vesanoid (tretinoin)
    9ms
    Lysari: Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma (clinicaltrials.gov)
    P3, N=460, Recruiting, Centre Leon Berard | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Erbitux (cetuximab) • cisplatin • Vesanoid (tretinoin)
    11ms
    STARPAC2: A Randomised Trial of ATRA in a Novel Drug Combination for Pancreatic Cancer (clinicaltrials.gov)
    P2, N=170, Active, not recruiting, Queen Mary University of London | Trial completion date: May 2025 --> Feb 2029 | Trial primary completion date: Nov 2024 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    gemcitabine • albumin-bound paclitaxel • Vesanoid (tretinoin)
    12ms
    A Study of TAS1440 With ATRA in Subjects With r/r AML (clinicaltrials.gov)
    P1, N=52, Terminated, Taiho Oncology, Inc. | N=80 --> 52 | Trial completion date: Dec 2025 --> Feb 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2025 --> Feb 2024; The study was terminated due to the changing treatment landscape, difficulty in enrolling eligible participants, and little likelihood of providing meaningful clinical benefit for the participants.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy
    |
    Vesanoid (tretinoin)
    1year
    Lysari: Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma (clinicaltrials.gov)
    P3, N=460, Not yet recruiting, Centre Leon Berard
    New P3 trial
    |
    Erbitux (cetuximab) • cisplatin • Vesanoid (tretinoin)